HK Stock Movement | FUSEN PHARM (01652) Surges Nearly 74% Intraday as Enzalutamide Soft Capsule Approved and Metformin Empagliflozin Tablet Included in National Bulk-Buy Program

Stock News

10/31

FUSEN PHARM (01652) surged nearly 74% intraday, and as of the latest update, the stock was up 49.28% at HKD 1.03, with a turnover of HKD 10.37 million. The company announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) for its Enzalutamide Soft Capsule. The drug is approved for treating adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis, as well as adult patients with metastatic castration-resistant prostate cancer (CRPC) who have failed androgen deprivation therapy (ADT) and show no or mild symptoms without prior chemotherapy.

Additionally, FUSEN PHARM disclosed that its Metformin Empagliflozin Tablet (I) (containing 500mg metformin hydrochloride and 5mg empagliflozin) has been preliminarily selected in China's 11th national bulk drug procurement program. The company had previously announced in September that the NMPA had approved the market application for this product.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1177679917"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177679917\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177679917?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 10:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177679917","market":"us","top_or_hot":-1,"title":"HK Stock Movement | FUSEN PHARM (01652) Surges Nearly 74% Intraday as Enzalutamide Soft Capsule Approved and Metformin Empagliflozin Tablet Included in National Bulk-Buy Program","media":"Stock News","content":"<p>FUSEN PHARM (01652) surged nearly 74% intraday, and as of the latest update, the stock was up 49.28% at HKD 1.03, with a turnover of HKD 10.37 million. The company announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) for its Enzalutamide Soft Capsule. The drug is approved for treating adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis, as well as adult patients with metastatic castration-resistant prostate cancer (CRPC) who have failed androgen deprivation therapy (ADT) and show no or mild symptoms without prior chemotherapy.</p>\n<p>Additionally, FUSEN PHARM disclosed that its Metformin Empagliflozin Tablet (I) (containing 500mg metformin hydrochloride and 5mg empagliflozin) has been preliminarily selected in China's 11th national bulk drug procurement program. The company had previously announced in September that the NMPA had approved the market application for this product.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | FUSEN PHARM (01652) Surges Nearly 74% Intraday as Enzalutamide Soft Capsule Approved and Metformin Empagliflozin Tablet Included in National Bulk-Buy Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | FUSEN PHARM (01652) Surges Nearly 74% Intraday as Enzalutamide Soft Capsule Approved and Metformin Empagliflozin Tablet Included in National Bulk-Buy Program\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-10-31 10:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>FUSEN PHARM (01652) surged nearly 74% intraday, and as of the latest update, the stock was up 49.28% at HKD 1.03, with a turnover of HKD 10.37 million. The company announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) for its Enzalutamide Soft Capsule. The drug is approved for treating adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis, as well as adult patients with metastatic castration-resistant prostate cancer (CRPC) who have failed androgen deprivation therapy (ADT) and show no or mild symptoms without prior chemotherapy.</p>\n<p>Additionally, FUSEN PHARM disclosed that its Metformin Empagliflozin Tablet (I) (containing 500mg metformin hydrochloride and 5mg empagliflozin) has been preliminarily selected in China's 11th national bulk drug procurement program. The company had previously announced in September that the NMPA had approved the market application for this product.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01652","symbol_name":"福森藥業","start_time":0,"source_url":"","article_id":"1177679917","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177679917","pubTimestamp":1761878056,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FUSEN PHARM (01652) surged nearly 74% intraday, and as of the latest update, the stock was up 49.28% at HKD 1.03, with a turnover of HKD 10.37 million. The company announced that its wholly-owned...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01652":"福森药业","BK1191":"制药"},"translate_title":"港股动向|福森药业(01652)盘中大涨近74%因恩杂鲁胺软胶囊获批、二甲双胍恩格列净片纳入国家带量采购计划","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01652":1},"content_text":"FUSEN PHARM (01652) surged nearly 74% intraday, and as of the latest update, the stock was up 49.28% at HKD 1.03, with a turnover of HKD 10.37 million. The company announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) for its Enzalutamide Soft Capsule. The drug is approved for treating adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis, as well as adult patients with metastatic castration-resistant prostate cancer (CRPC) who have failed androgen deprivation therapy (ADT) and show no or mild symptoms without prior chemotherapy.\nAdditionally, FUSEN PHARM disclosed that its Metformin Empagliflozin Tablet (I) (containing 500mg metformin hydrochloride and 5mg empagliflozin) has been preliminarily selected in China's 11th national bulk drug procurement program. The company had previously announced in September that the NMPA had approved the market application for this product.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}